<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940548</url>
  </required_header>
  <id_info>
    <org_study_id>2016PHB013-02</org_study_id>
    <nct_id>NCT02940548</nct_id>
  </id_info>
  <brief_title>Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness</brief_title>
  <acronym>NARRAS</acronym>
  <official_title>A Comparative Study for the Effects of Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness in the Young and Middle-aged Subjects With Non-dipper Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jing Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the effects of Nifedipine GITS and Amlodipine besylate on blood pressure
      rhythm restoration and arterial stiffness in young and middle-aged non-dipper hypertensives.
      Half of participants will receive Nifedipine GITS, half of half will take medicine in the
      morning or at night. While the other half participants will take amlodipine besylate, whom
      will also be assigned taking medicine in the morning or at night. Ambulatory blood pressure
      monitoring and arterial stiffness examination will be performed before and after
      pharmaceutical intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Written informed consent will obtained from all the participants. All the adverse reaction or
      adverse event, related or unrelated to the study drug, will be recorded in detail, including
      the occurrence time, symptoms and vital signs, degree, duration, laboratory test indexes,
      treatment methods and results, process, follow-up time, etc.

      If serious adverse event occurs, study drugs should be stopped and necessary remedy should be
      delivered immediately. At the same time, the investigator must report it to the local drug
      supervision, medical ethics committee and China Food and Drug Administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nighttime systolic blood pressure reduction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Compare the effects of two active drugs on nighttime systolic blood pressure reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of recovery of dipper rhythm of blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Compare the effects of two active drugs and different time administration on recovery of dipper rhythm. The proportion of blood pressure dipper rhythm at 8 weeks after two drugs administration will be calculated. The proportion of dipper rhythm at 8 weeks after two drugs administration in the morning or at night will also be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pulse wave velocity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Compare the effects of two active drugs on pulse wave velocity(PWV). PWV will be measured before and after 8 weeks two active drugs administration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>change of heart rate; change of liver and kidney function; other adverse reactions, such as edema, flushing, etc during 8 weeks of intervention and follow-ups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nifedipine GITS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nifedipine GITS 30~60mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine besylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine besylate 5~10mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine GITS</intervention_name>
    <description>Nifedipine GITS 30~60mg/day for 8 weeks</description>
    <arm_group_label>Nifedipine GITS</arm_group_label>
    <other_name>Adalat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate</intervention_name>
    <description>Amlodipine besylate 5~10mg/day for 8 weeks</description>
    <arm_group_label>Amlodipine besylate</arm_group_label>
    <other_name>Norvasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate (Office blood pressure : 140 mmHg =&lt; systolic blood pressure (SBP)
             &lt;180 mmHg and / or 90 mmHg =&lt; diastolic blood pressure (DBP) &lt;110 mmHg) , non-dipper
             (ambulatory blood pressure monitoring (ABPM): night-time mean SBP / day-time mean SBP
             &gt;=0.9 and night-time mean SBP &gt;=120 mmHg) hypertensive subjects, who is drug
             treatment-naive or previously treated but discontinued for 2 weeks or more

          -  The subject is voluntary to participate in the study and has signed the informed
             consent form

        Exclusion Criteria:

          -  Known allergy to any component of Nifedipine and Amlodipine

          -  Office SBP &gt;=180 mmHg and / or DBP &gt;=110 mmHg in the screening period

          -  The patient who is taking calcium antagonists (monotherapy or combination with other
             drugs)

          -  Evidences of secondary hypertension

          -  History of cerebrovascular events, cardiac failure, serious coronary artery disease
             within 12 months

          -  Type 1 diabetes mellitus (DM)

          -  Severe liver diseases or renal insufficiency

          -  The pregnant woman, the woman who may be pregnant or plan to be pregnant, or the
             lactating woman

          -  The subject who needs to work at night (on night shift)

          -  Other reasons that the subject can not participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Liu, M.D.</last_name>
    <phone>861088325457</phone>
    <email>heartcenter@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Liu, M.D.</last_name>
      <phone>861088325457</phone>
      <email>heartcenter@163.com</email>
    </contact>
    <investigator>
      <last_name>Jing Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, de la Cruz JJ, Sobrino J, Llisterri JL, Alonso J, Vinyoles E, Pallarés V, Sarría A, Aranda P, Ruilope LM; Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 2009 Mar;53(3):466-72. doi: 10.1161/HYPERTENSIONAHA.108.124008. Epub 2009 Jan 26.</citation>
    <PMID>19171788</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Jing Liu</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>non-dipper hypertension</keyword>
  <keyword>young</keyword>
  <keyword>middle-aged</keyword>
  <keyword>ambulatory blood pressure monitoring</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>nifedipine gastrointestinal therapeutic system (GITS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

